These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 19416627

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss S.
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
    Moore RA, Derry S, McQuay HJ.
    BMC Musculoskelet Disord; 2007 Aug 03; 8():73. PubMed ID: 17683540
    [Abstract] [Full Text] [Related]

  • 8. Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs.
    Patrono C.
    Curr Cardiol Rep; 2016 Mar 03; 18(3):25. PubMed ID: 26841787
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs.
    Scheiman JM, Fendrick AM.
    Arthritis Res Ther; 2005 Mar 03; 7 Suppl 4(Suppl 4):S23-9. PubMed ID: 16168078
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk.
    Vardeny O, Solomon SD.
    Cardiol Clin; 2008 Nov 03; 26(4):589-601. PubMed ID: 18929233
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Channeling and prevalence of cardiovascular contraindications in users of cyclooxygenase 2 selective nonsteroidal antiinflammatory drugs.
    Mosis G, Stijnen T, Castellsague J, Dieleman JP, van der Lei J, Stricker BH, Sturkenboom MC.
    Arthritis Rheum; 2006 Aug 15; 55(4):537-42. PubMed ID: 16874797
    [Abstract] [Full Text] [Related]

  • 18. [Further definition of the role of COX-2 inhibitors and NSAIDs in patients with nociceptive pain].
    Nurmohamed MT.
    Ned Tijdschr Geneeskd; 2007 Jun 09; 151(23):1313; author reply 1313-4. PubMed ID: 17624165
    [No Abstract] [Full Text] [Related]

  • 19. [Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs].
    van den Bemt BJ, Benraad HB, Rasker JJ.
    Ned Tijdschr Geneeskd; 2007 May 12; 151(19):1062-7. PubMed ID: 17552414
    [Abstract] [Full Text] [Related]

  • 20. The COXIB experience: a look in the rearview mirror.
    Marnett LJ.
    Annu Rev Pharmacol Toxicol; 2009 May 12; 49():265-90. PubMed ID: 18851701
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.